# US 8,569,347 B2 · Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,347 B2
- Document ID: US8569347B2
- Status: Granted
- Kind: B2
- Application number: 10/850,072
- Filed: 2004-05-20
- Published: 2004-10-28
- Granted: 2013-10-29
- Earliest claimed: 2001-03-14
- Assignees: Bristol-Myers Squibb Company
- Applicants: Francis Y. F. Lee
- Inventors: Francis Y. F. Lee
- Web page: https://patentgrep.com/patent/US8569347B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/33: Heterocyclic compounds
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/365: Lactones
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 5/38: of the suprarenal hormones
- A61P 5/44: Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
- A61P 5/46: for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.

## Claims

### Claim 1

A method for treating lung cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula,
or a pharmaceutically-acceptable hydrate, solvate, or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

### Claim 2 (depends on 1)

The method of claim 1 wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

### Claim 3 (depends on 1)

The method of claim 1 wherein the antibody C225 is administered following the administration of Compound (1).

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody C225 is administered before the administration of Compound (1).

### Claim 5 (depends on 1)

The method according to claim 1, wherein the antibody C225 is administered substantially simultaneously with the administration of Compound (1).

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antibody C225 and the Compound (1) are both administered parenterally.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the cancer is non-small cell lung cancer.

### Claim 8

A method for treating pancreatic cancer, which comprises administering to a mammal a combination therapy comprising a dosage unit of Compound (1), having the formula,
and/or a pharmaceutically-acceptable hydrate, solvate, and/or geometric, optical or stereoisomer of Compound (1), and a dosage unit of at least a second chemotherapeutic agent comprising antibody C225, wherein the combination therapy will provide a greater anti-cancer effect than the effect obtainable with either the dosage unit of Compound (1) or the antibody C225 alone.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.

### Claim 10 (depends on 7)

The method of claim 7, wherein the cancer is refractory, resistant, and/or sensitive to taxane treatment.